SIVB 2021: In Vitro OnLine is almost here!
We are moving quickly forward with plans for the virtual SIVB annual meeting, SIVB 2021: In Vitro OnLine, from June 5 – 9, 2021 and are so excited to share this year’s program with you all. Learn more about the program from this year’s Program Chairs.
Check out the new schedule!
SIVB 2021 In Vitro OnLine will be presented using Eastern Daylight Time. Because with a virtual program, attendees can be watching from all over the world, we have made some adjustments to our daily schedule to accommodate our international audience. Please check out the new schedule times. Plenary sessions have been adjusted to start at 9:00 am EDT which should make it a bit more manageable for those throughout the US and in many other time zones. Poster sessions are being scheduled for all attendees. Most other sessions are close to or at the same times as they have been in prior events.
We want to see you there!
We are looking forward to your active participation in this year’s event. SIVB will be offering a combination of live streaming sessions where speakers will answer questions on screen and some prerecorded presentations released with speakers available to answer your questions behind the scenes, but in real time as scheduled in the program. There will be video chats and scheduled social events to network with each other face to face! We are also thrilled to share that we will be welcoming back our exhibitors with Exhibitor’s Spotlight Presentations and a special video chat hour for you to meet them during the event.
There are so many opportunities for you to join us:
- Group Registration is available if you have at least 5 regular members from your organization who all want to attend this year’s event. Contact our office to request the group registration form to register all your colleagues at one discounted rate! The more people you have registering, the better your discounts will be!
- Abstract submission is available through March 31 and there are still opportunities for oral presentations as well as poster presentations, so get your research in before the deadline passes!
- Advanced Registration is available through May 4, so make sure to save your spot so you can be in the (virtual) room where it happens! There are even special rates for Combintation Membership and Meeting Registration available!
Between live streaming sessions with live Q&A, video chats, scheduled social networking events & much more, SIVB 2021 is virtual but has all the bells and whistles of a live event
Oral Presentation Opportunities through March 31, 2021
The Society for In Vitro Biology (SIVB) will be in the palm of your hand at SIVB 2021: In Vitro OnLine! Taking place from June 5 – 9, 2021, this virtual annual meeting is a wonderful opportunity to network with experts in your field to examine the foundations and innovations of in vitro plant and animal biotechnology research. SIVB’s Program Committee encourages you to submit abstracts of your work for presentation. We are so excited about this opportunity that we are extending the deadline to have your work considered oral presentation. Visit our Abstract Submission page to learn more about how to pay for and submit your abstract. The Final Submission Deadline to have your abstract considered for Oral or Poster presentation is March 31, 2021.
SIVB Welcomes Keynote Speaker Dr. J. Keith Joung
On Sunday, June 6, Dr. Joung will speak on “CRISPR-based technologies for targeted genome editing and gene regulation.” Dr. Joung is a leading innovator in the field of gene editing. He is the Robert B. Colvin, M.D. Endowed Chair in Pathology, Desmond and Ann Heathwood Research Scholar, and a Pathologist at Massachusetts General Hospital (MGH) and Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. Dr. Joung has been a pioneer in the development of important technologies for targeted gene editing and epigenetic editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the MGH Research Scholar Award, an NIH R35 MIRA (Maximizing Investigators Research Award), election into the American Association of University Pathologists, and designation as a “Highly Cited Researcher” in 2016, 2017, 2018, and 2019 by Thomson Reuters/Clarivate Analytics. He serves on the editorial boards of Genome Biology, Human Gene Therapy, and Trends in Biotechnology. He has co-founded and advises multiple biotechnology companies including Editas Medicine, Beam Therapeutics, Pairwise, and Verve Therapeutics. Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. in biochemical sciences from Harvard College.